The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Volumn 15, Issue 5, 2007, Pages 342-345

  Jia, Ji dong ^a   Hou, Jin lin ^b   Yin, You kuan ^b   Xu, Dao zhen ^b   Tan, De ming ^b   Niu, Jun qi ^b   Zhou, Xia qiu ^b   Wang, Yu ming ^b   Zhu, Li min ^b   He, Yong wen ^b   Ren, Hong ^b   Wan, Mo bin ^b   Chen, Cheng wei ^b   Wu, Shan ming ^b   Chen, Ya gang ^b   Xu, Jia zhang ^b   Wang, Qin huan ^b   Wei, Lai ^b   Ma, Hong ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE; PYRIMIDINONE DERIVATIVE; TELBIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEPATITIS B; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NUCLEOSIDES; PYRIMIDINONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 34548355564     PISSN: 10073418     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)